These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 4358481)

  • 41. [Immunization against SV40 tumor virus; antigenic relationship between embryonic hamster cells and cells transformed by SV40].
    Houle G; Richer G; Dubreuil R; Borduas AG
    Can J Microbiol; 1974 Mar; 20(3):379-83. PubMed ID: 4362600
    [No Abstract]   [Full Text] [Related]  

  • 42. Effective anti-tumor immunity induced in mice by a two-step vaccination protocol.
    Martino A; Vismara D; Cicconi R; Delpino A; Ivanyi J; Colizzi V; Cassol M; Fraziano M; Piselli P
    In Vivo; 2001; 15(5):425-8. PubMed ID: 11695241
    [TBL] [Abstract][Full Text] [Related]  

  • 43. T-T cell collaboration in rejection of a syngeneic SV40-induced sarcoma in mice.
    Glasser M; Law LW
    Nature; 1978 Jun; 273(5661):385-7. PubMed ID: 207992
    [No Abstract]   [Full Text] [Related]  

  • 44. Fetal antigens shared as transplantation rejection antigens on chemically induced mouse and hamster sarcomas.
    Coggin JH; Adkinson L; Anderson NG
    Cancer Res; 1980 May; 40(5):1568-73. PubMed ID: 6768448
    [No Abstract]   [Full Text] [Related]  

  • 45. CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen.
    Kennedy RC; Shearer MH; Watts AM; Bright RK
    Cancer Res; 2003 Mar; 63(5):1040-5. PubMed ID: 12615720
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Specific simian virus 40 (SV40)-induced immunity against transplantable SV40 tumor in Syrian hamsters: abrogation by BCG vaccination.
    Zhalgasbayeva GT; Deichman GI
    J Natl Cancer Inst; 1977 Apr; 58(4):1121-4. PubMed ID: 191624
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunobiological studies of tumors induced by murine sarcoma virus (Kirsten).
    McCoy JL; Fefer A; McCoy NT; Kirsten WH
    Cancer Res; 1972 Feb; 32(2):343-9. PubMed ID: 4333497
    [No Abstract]   [Full Text] [Related]  

  • 48. Immune reactions against hepatitis B viral antigens lead to the rejection of hepatocellular carcinoma in BALB/c mice.
    Chen SH; Hu CP; Lee CK; Chang C
    Cancer Res; 1993 Oct; 53(19):4648-51. PubMed ID: 8402642
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor-induced skin heterogenization. II. Virus causing the phenomenon.
    Svet-Moldavsky GJ; Liozner AL; Mkheidze DM; Sokolov PP; Bykovsky AP
    J Natl Cancer Inst; 1970 Sep; 45(3):475-84. PubMed ID: 4943064
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of adherent cells in tumor immunity.
    Burk MW; Yu S; McKhann CF
    Surg Forum; 1975; 26():140-2. PubMed ID: 1216090
    [No Abstract]   [Full Text] [Related]  

  • 51. Tumor immunity in hamsters immunized with fetal tissues.
    Coggin JH; Ambrose KR; Bellomy BB; Anderson NG
    J Immunol; 1971 Aug; 107(2):526-33. PubMed ID: 4328010
    [No Abstract]   [Full Text] [Related]  

  • 52. B7-1 and interleukin 12 synergistically induce effective antitumor immunity.
    Coughlin CM; Wysocka M; Kurzawa HL; Lee WM; Trinchieri G; Eck SL
    Cancer Res; 1995 Nov; 55(21):4980-7. PubMed ID: 7585539
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Relationship between foreign H-2-like antigens on MCG4 sarcoma and the in vivo rejection of this tumor by syngeneic and semisyngeneic mice.
    García-Olivares E; Torres MD; Gutiérrez F; Osorio C
    Rev Esp Fisiol; 1982 Mar; 38(1):9-12. PubMed ID: 7100610
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Suppression of SV40 tumors after immunization with group A Streptococcus pyogenes and Bordetella pertussis.
    Collins JL; Wust CJ
    Cancer Res; 1974 May; 34(5):932-7. PubMed ID: 4363064
    [No Abstract]   [Full Text] [Related]  

  • 55. Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors.
    Eiselein J; Biggs MW
    Cancer Res; 1970 Jul; 30(7):1953-7. PubMed ID: 4989547
    [No Abstract]   [Full Text] [Related]  

  • 56. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
    Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
    Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lysozyme enhancement of tumor cell immunoprotection in a murine fibrosarcoma.
    Warren JS; Rinehart JJ; Zwilling BS; Neidhart JA
    Cancer Res; 1981 May; 41(5):1642-5. PubMed ID: 7214334
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunity to murine sarcoma virus (MSV)-induced tumors demonstrated by "in vivo" elimination of 51-chromium labeled tumor cells.
    Burstein NA
    Rev Eur Etud Clin Biol; 1970 Oct; 15(8):873-5. PubMed ID: 4322224
    [No Abstract]   [Full Text] [Related]  

  • 59. [Tumor radiotherapy and immune status of the host in an allogenic system].
    Deneufbourg JM
    Bull Cancer; 1972; 59(1):61-76. PubMed ID: 4117668
    [No Abstract]   [Full Text] [Related]  

  • 60. Augmented immunogenicity of tumor cell homogenates produced by infection with influenza virus.
    Boone CW
    Natl Cancer Inst Monogr; 1972 Dec; 35():301-7. PubMed ID: 4349150
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.